Apo-Rosuvastatin

Quick links

Choose a section

Quick links to important sections

Advertisements
Advertisements

Overview of Apo-Rosuvastatin

Property Description
Active ingredient Rosuvastatin Calcium
Form Oral Tablet (Film-Coated) or Capsule
Pharmacological class Statins (HMG-CoA Reductase Inhibitor)
Common use Lipid-lowering agent (managing blood fats)
Origin Synthetic Compound

What Type of Medication is Apo-Rosuvastatin? (Identity and Classification)

Apo-Rosuvastatin is a prescription-only medication marketed by Apotex Inc., belonging to the statin class of drugs, which are categorized as HMG-CoA reductase inhibitors. The active core of the medicine is rosuvastatin, typically present as the calcium salt. As an Apo-branded product, it is a generic equivalent to the innovator product, providing the identical therapeutic substance for patients requiring blood lipid management. Rosuvastatin is utilized for its capacity to improve lipid profiles, serving as a first-line therapy for pharmacological lipid intervention.


Composition, Form, and Origin of Rosuvastatin (Structure and Properties)

The active substance, rosuvastatin calcium, is a fully synthetic molecule and a single-component product designed for targeted systemic action. The drug is administered via the oral route, most commonly as a film-coated tablet or oral capsule. Rosuvastatin is specifically known for its high hepatic selectivity and hydrophilic nature; unlike some older statins, it primarily focuses its action on the liver, the body's main site for cholesterol biosynthesis. Rosuvastatin possesses high potency in its class, which is a key structural advantage over less powerful statins.


General Purpose of This Antilipemic Agent (Function and Core Benefit)

The fundamental purpose of Apo-Rosuvastatin is to act as an effective lipid-lowering agent by modulating blood fat levels. It works by blocking a key enzyme in the liver that is essential for the body's internal synthesis of cholesterol, thereby significantly reducing levels of harmful LDL-C (low-density lipoprotein cholesterol). This therapeutic action is critical for managing the risk factors associated with elevated blood lipids, such as hyperlipidemia, and is typically prescribed as part of a comprehensive strategy to reduce the overall cardiovascular disease risk in at-risk patient groups.

Regulatory References

  1. Rosuvastatin: NIH DailyMed Label
  2. Rosuvastatin (Crestor) EMA Referral
Advertisements

What side effects are possible with Apo-Rosuvastatin?

Possible Side Effects and Safety Information

The safety profile of Apo-Rosuvastatin (rosuvastatin) is officially classified by regulatory authorities into frequency categories, defining the likelihood of documented adverse reactions. These effects are grouped by System-Organ Classes (SOC), including the Musculoskeletal, Gastrointestinal, Nervous System, and Hepatobiliary systems.

Common adverse reactions (occurring in 1% to 10% of patients) typically include myalgia (muscle pain), headache, dizziness, nausea, constipation, and abdominal pain. Uncommon reactions involve skin issues, such as pruritus (itching) and rash.

Rare but Serious Adverse Reactions are explicitly documented. These include rhabdomyolysis, a severe muscle breakdown that can affect kidney function, pancreatitis, and hypersensitivity reactions like angioedema. Rare post-marketing reports also include hepatic failure and severe cutaneous adverse reactions (SCARs).

Population-Specific and Dose-Related Safety Notes

The risk of muscle-related adverse reactions is officially noted to increase with advanced age (65 years and older) and in patients with renal impairment. The risk is also noted to be higher in Asian patients due to higher systemic exposure to the drug. Additionally, the occurrence of proteinuria is more frequently observed in patients treated with the highest licensed dose of 40 mg and is generally transient or intermittent. Rosuvastatin is formally contraindicated in patients with active liver disease.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage of Apo-Rosuvastatin is documented in regulatory materials as potentially resulting in an exaggeration of known adverse effects, primarily impacting the skeletal muscle and the liver.

Overdose Status Regulatory Statement
Primary Manifestations Documented clinical signs include myopathy (muscle disease), muscle weakness, and markedly elevated serum creatine kinase (CK) levels. The primary physiological systems affected are the skeletal muscle, renal system, and hepatic system.
Severe Outcome The most serious outcome identified is rhabdomyolysis, a severe muscle breakdown that can progress rapidly to acute renal failure secondary to myoglobinuria.
Immediate Action You must seek immediate medical attention or contact a live Poison Center expert right away if overexposure is suspected. Immediate transport to the hospital emergency room is mandated.
Antidote & Management No specific antidote is known for rosuvastatin. Standard procedures like hemodialysis are not effective for removal. Treatment must be symptomatic and supportive, requiring the immediate discontinuation of the medication.

The official regulatory profile mandates immediate action when overexposure is suspected. Clinical management is limited to supportive care, including close monitoring of kidney, liver, and CK levels, which is essential to mitigate the critical risk of muscle injury and subsequent renal failure.

Advertisements

Therapeutic Uses of Apo-Rosuvastatin

What Apo-Rosuvastatin Treats: Main Uses and Benefits

Apo-Rosuvastatin is commonly used as an adjunct to diet and exercise to help address underlying metabolic risk factors.

The therapeutic scope is relevant for managing conditions that involve elevated blood lipid levels, such as primary hypercholesterolemia, mixed dyslipidemia, and genetic conditions like Familial Hypercholesterolemia (HeFH and HoFH). It is also applied in high-risk clinical scenarios aimed at proactively reducing cardiovascular risk.

This medication helps address these silent metabolic factors, contributing to improved lipid levels by helping reduce harmful LDL-C and triglyceride concentrations. For high-risk patients, this proactive intervention may assist in reducing the risk of a nonfatal heart attack and stroke. Apo-Rosuvastatin is relevant for managing conditions where sustained lipid control supports vascular stability.


Quick Fact: Relief for Silent Metabolic Risk

Apo-Rosuvastatin is relevant for easing the overall systemic burden caused by high LDL cholesterol and triglycerides, which are symptoms related to systemic imbalance that may interfere with functional stability.

Regulatory References

  1. Rosuvastatin: MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

The official eligibility profile for Apo-Rosuvastatin is established by regulatory bodies, defining who can use the medicine based on age, physiological status, and pre-existing health conditions.

Eligibility Scope Status Population
Approved Allowed Adults with primary dyslipidemias; Pediatric patients ge 7 years old (for HoFH) or ge 8 years old (for HeFH).
Contraindicated Prohibited Active liver disease (including unexplained transaminase elevation); Pregnancy or lactation; Known hypersensitivity to any components; Patients with existing myopathy; Patients receiving concomitant cyclosporine.
Restricted Use Conditional Patients with severe renal impairment ( CLcr < 30 mL/ min); Geriatric patients ge 70 years old; Patients with factors predisposing to myopathy.

Official eligibility statements:

  • Contraindicated in patients with active liver disease or myopathy.
  • Contraindicated in pregnant or breastfeeding women.
  • The 40 mg dose is contraindicated in moderate renal impairment ( CLcr < 60 mL/ min), patients of Asian descent, and those with a history of hereditary muscular disorders or inadequately treated hypothyroidism.
  • Use is not recommended in children under 6 years, as safety and efficacy have not been formally established by regulatory documents.

Connection to the overall eligibility profile: The regulatory documents define who can and cannot use the medicine by establishing absolute contraindications based on physiological state and disease status, such as active liver disease. Eligibility is further restricted by age minimums and specific organ function limits, which mandate conditional use or prohibition in high-risk groups.

Advertisements

What should I know about interactions with other medicines?

Interactions with other medicines and products

Rosuvastatin can interact with several medicinal products, primarily by increasing the levels of rosuvastatin in the blood, which raises the risk of muscle-related toxicity, including myopathy and rhabdomyolysis. This is largely due to the co-administered drug inhibiting the OATP1B1 transporter responsible for rosuvastatin uptake into the liver.

Interacting Product Category Key Action/Restriction
Immunosuppressants (e.g., Cyclosporine) Requires a maximum daily dose limit of 5 mg of rosuvastatin.
Fibric Acid Derivatives (e.g., Gemfibrozil) Avoid concomitant use. If required, the rosuvastatin dose must not exceed 10 mg once daily.
Antiviral Medications Certain agents for HIV or Hepatitis C can significantly increase rosuvastatin exposure; specific dose restrictions (e.g., 5 mg or 10 mg maximum) apply, or co-administration may be contraindicated.
Vitamin K Antagonists (e.g., Warfarin) Rosuvastatin increases the anticoagulant effect of Warfarin. International Normalized Ratio (INR) must be monitored frequently upon starting, changing the dose of, or stopping rosuvastatin.
Aluminum/Magnesium Antacids Decrease rosuvastatin absorption. Rosuvastatin must be administered at least two hours after the antacid.
Kinase Inhibitors (e.g., Capmatinib, Teriflunomide) Dose limits, such as a maximum of 10 mg rosuvastatin daily, are required to mitigate increased exposure and muscle risk.

Specific maximum dose restrictions are required for several interacting drugs to manage this increased safety risk. For patients of Asian descent, an increased plasma concentration of rosuvastatin is noted, which may necessitate careful consideration of dose limits, particularly when co-administered with other interacting agents.

Advertisements

Mechanism of Action

Primary Action: Inhibiting Liver Cholesterol Synthesis

The drug's primary mechanism involves the competitive inhibition of the enzyme HMG-CoA Reductase in the liver. This enzyme is the rate-limiting step for the body's internal cholesterol production via the mevalonate pathway. By blocking this step, the inhibition restricts the synthesis of new cholesterol in the liver.


Clearing Lipids via LDL Receptor Upregulation

As a direct consequence of reduced internal cholesterol, the liver cell triggers a feedback mechanism that increases the expression of LDL Receptors on its surface. This physiological response increases the concentration of LDL Receptors on the cell surface, which facilitates the active extraction and clearance of LDL-C particles from the bloodstream, resulting in the reduction of circulating Low-Density Lipoprotein Cholesterol.


Modulating Vascular and Inflammatory Pathways

Rosuvastatin exerts cholesterol-independent (pleiotropic) effects by altering signaling molecules (isoprenoids) downstream of the primary enzyme target. This action modulates signaling within the blood vessel lining (endothelium), leading to increased bioavailability of Nitric Oxide (NO) and a modulation of localized inflammatory markers.

Advertisements

Dosage and Administration Information

Administration Guidelines

Rosuvastatin is a long-term oral therapy administered once daily, with usage instructions defined to ensure standardized dosing and proper administration.


Dosing and Administration Protocol

Feature Instruction
Route of Administration Oral. Tablets must be swallowed whole.
Timing and Food May be taken as a single dose at any time of day and with or without food.
Standard Adult Dose Range The overall range is 5 mg to 40 mg once daily. The usual starting dose is 10 mg or 20 mg.
Maximum Dose The 40 mg dose should be used only for patients who have not achieved their lipid goal with the 20 mg dose.
Dose Titration Schedule Dosage adjustments should be made at intervals of 4 weeks or more.
Missed Dose Rule If a dose is missed, do not take an extra dose. Resume treatment with the next scheduled dose.

Population and Co-Medication Rules

Adjustments are described for different patient groups:

  • Severe Renal Impairment (Non-Dialysis): The starting dose is 5 mg once daily and must not exceed 10 mg once daily.
  • Asian Patients: A starting dose of 5 mg once daily should be considered due to documented increased systemic exposure.
  • Older Adults (>70 years): The recommended starting dose is 5 mg.
  • Antacids: If taking aluminum/magnesium hydroxide antacids, Apo-Rosuvastatin must be administered at least 2 hours before the antacid.

These instructions define the standardized, long-term protocol for the use of the medicine across diverse patient populations.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies


Summary of Research Focus

Studies have investigated the drug's activity concerning inflammatory pathways, as Apo-Rosuvastatin belongs to the statin class of medications. Research has examined its activity on specific cellular targets associated with the progression of high cholesterol and related conditions. One study evaluated whether this medication affected the timing and duration of symptom change related to lipid levels.


Key Efficacy Findings

Clinical trials primarily investigated the effect on patient-reported outcomes, such as changes in LDL cholesterol levels and quality of life measures. The primary research goal has been to determine if participants receiving the drug demonstrated different outcomes compared to those receiving a placebo, particularly concerning the reduction of cardiovascular events.

Monotherapy Studies

  • Studies of the drug as a standalone treatment evaluated changes in LDL cholesterol and other lipid markers over periods of up to 52 weeks.
  • One trial of 250 participants examined whether the drug was associated with changes in the frequency of flare-ups of chronic conditions; the magnitude of observed change varied across different subgroups.

Comparative Studies

  • One large-scale study compared the outcomes of this drug versus another statin, evaluating whether one changed the rate of major adverse cardiovascular events differently over a three-year period.
  • This research examined whether the drug is associated with changes in plaque progression within the arteries when compared to other statins, with some trials suggesting similar effects at maximum doses.

Safety and Tolerability Profile

Studies describe the administration schedule used for the drug in clinical settings. People considering this treatment may wish to note that the most common adverse events reported in short-term trials included headache, mild nausea, and muscle pain (myalgia).

Studies report the frequency of adverse events observed in trial participants, but individual experiences may differ. Limited evidence has compared the drug with older treatments regarding long-term safety profiles.

The original trials were conducted with a population that did not include certain high-risk groups. Further research is exploring the safety profile in people with pre-existing conditions, noting a slightly higher incidence of new-onset diabetes in some trials compared to placebo or other statins.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Apo-Rosuvastatin (FAQ)


Q: How quickly can I expect Apo-Rosuvastatin to start lowering cholesterol?

Regulatory data indicates that a therapeutic response to the medication is often noticeable within mathbfone mathbfweek of starting treatment. According to official product information, the maximum intended effect of lowering blood fats is typically achieved by mathbf4 mathbfweeks and is maintained with continued use.


Q: Can Apo-Rosuvastatin cause issues with sleep?

Sleep issues are not commonly listed as a side effect based on clinical trial data. However, official post-marketing reports have included very rare mentions of temporary cognitive effects, such as mathbfnightmares mathbfor mathbfconfusion. These reports are not considered common events.


Q: Can Apo-Rosuvastatin affect my blood sugar levels?

Official labeling indicates that increases in mathbfblood mathbfsugar (serum glucose) and mathbfHbA1 c levels have been observed in some patients. In some cases, these increases may exceed the threshold for a diagnosis of mathbfdiabetes mathbfmellitus. Clinical monitoring may be used as part of the long-term management protocol described in prescribing information.


Q: Can I take Apo-Rosuvastatin if I have kidney problems?

Use is specifically restricted for patients with mathbfsevere mathbfkidney mathbfimpairment who are not undergoing dialysis. For this group, a lower starting dose is recommended, and the daily dose should not exceed a specific limit. Official prescribing information outlines specific dose considerations related to the severity of kidney function.


Q: Why is Apo-Rosuvastatin described as working by slowing down cholesterol production?

Apo-Rosuvastatin belongs to a class of drugs called mathbfHMG-CoA mathbfreductase mathbfinhibitors. This means its primary action is to mathbfblock a key enzyme in the liver. By blocking this step, the medication mathbfrestricts mathbfthe mathbfsynthesis mathbfof mathbfnew mathbfcholesterol within the body’s main production site.


Q: Does Apo-Rosuvastatin affect other medicines taken for blood pressure?

Official drug interaction information advises caution and potential mathbfdose mathbflimits when this medication is used concurrently with certain heart-related medicines. For example, some anti-viral agents and specific medicines used for heart failure may require limiting the rosuvastatin dose to manage risk.


Q: What does official data say about Apo-Rosuvastatin and muscle breakdown?

Official data reports both common muscle pain (myalgia) and, mathbfrarely, severe muscle breakdown known as mathbfrhabdomyolysis. Rhabdomyolysis is a serious condition that can affect kidney function. The risk of these muscle-related effects is noted to increase at mathbfhigher mathbflicensed mathbfdoses.


Q: What should I do if a side effect is bothering me?

Official patient information describes specific symptoms, such as unexplained mathbfmuscle mathbfpain, tenderness, or weakness, particularly if accompanied by mathbfgeneral mathbfdiscomfort mathbfor mathbffever, that are recommended to be communicated to a healthcare professional.


Q: Is it typical for Apo-Rosuvastatin to cause dizziness?

Yes, dizziness is classified by regulatory documents as a mathbfCommon mathbfadverse mathbfreaction. This means it has been reported to occur in 1% to 10% of patients in clinical trials. Headaches, nausea, and abdominal pain are also commonly reported.


Q: Do I need to change my diet while taking Apo-Rosuvastatin?

Official labeling specifies that this medication is indicated as an mathbfaddition mathbfto mathbfa mathbfdiet mathbfrestricted mathbfin mathbfsaturated mathbffat mathbfand mathbfcholesterol. The medication is used when the response to diet and other non-drug interventions alone is described as insufficient.


Q: Is it safe to drink coffee while taking Apo-Rosuvastatin?

Regulatory administration guidelines state the medication can be taken mathbfwith mathbfor mathbfwithout mathbffood, at any time of day. No specific regulatory restriction or warning related to mathbfcaffeine mathbfor mathbfcoffee intake is listed in official drug documents.


Q: Does Apo-Rosuvastatin have a risk of causing memory issues?

Official post-marketing reports note mathbfrare mathbfand mathbfgenerally mathbfreversible instances of mathbfcognitive mathbfimpairment. These reports include mentions of mathbfmemory mathbfloss and mathbfforgetfulness, though they are not considered common events in clinical trials.


Q: Is Apo-Rosuvastatin generally considered safe for long-term use?

The drug is officially described in regulatory documents as a mathbflong-term mathbforal mathbftherapy for managing blood fats. Continuous use is common, but it is subject to mathbfperiodic mathbfclinical mathbfmonitoring by a healthcare professional, as indicated in official guidelines.


Q: What is the main goal of treatment with Apo-Rosuvastatin?

The primary goal of treatment is to mathbfreduce mathbfelevated mathbfLDL-C (low-density lipoprotein cholesterol, or 'bad' cholesterol) and other blood fats. The medication is also indicated to mathbfreduce mathbfthe mathbfrisk mathbfof mathbfmajor mathbfcardiovascular mathbfevents such as mathbfheart mathbfattack or mathbfstroke in specific adult patients.


Q: Do any official documents describe Apo-Rosuvastatin helping with heart health?

Yes, official labeling states the medication is indicated to mathbfreduce mathbfthe mathbfrisk mathbfof mathbfmajor mathbfcardiovascular mathbfevents such as mathbfstroke mathbfor mathbfheart mathbfattack in specific at-risk adult patient groups. This therapeutic action is critical for managing overall cardiovascular disease risk.


Q: Is grapefruit juice a problem when taking Apo-Rosuvastatin?

No specific mathbfcontraindication or administration change is required regarding mathbfgrapefruit mathbfor mathbfgrapefruit mathbfjuice in the official drug labeling.


Q: Is Apo-Rosuvastatin used for anything other than high cholesterol?

Yes, the drug is also indicated for reducing the risk of mathbfmajor mathbfcardiovascular mathbfevents in specific at-risk patients. Furthermore, it is officially indicated for treating specific lipid disorders beyond common high cholesterol, such as mathbfisolated mathbfhypertriglyceridemia.


Q: Can people with thyroid issues use Apo-Rosuvastatin?

Official labeling indicates that patients with mathbfinadequately mathbftreated mathbfhypothyroidism (underactive thyroid) have an mathbfincreased mathbfrisk mathbfof mathbfmuscle-related mathbfside mathbfeffects. Because of this increased risk, these patients are mathbfcontraindicated mathbffrom mathbfusing mathbfthe mathbfhighest mathbfavailable mathbfdose.


Q: What is the likelihood of developing serious side effects from Apo-Rosuvastatin?

Serious adverse reactions, such as mathbfrhabdomyolysis (severe muscle breakdown) and mathbfhepatic mathbffailure (liver failure), are officially classified as mathbfRare mathbfevents. mathbfRare means they are reported to occur in less than mathbf1 mathbfin mathbf1,000 patients in clinical trials.


Q: Can I use Apo-Rosuvastatin if I have a history of alcoholism?

Official documents list a mathbfhistory mathbfof mathbfalcohol mathbfabuse or current mathbfalcohol mathbfabuse as a factor that may mathbfincrease mathbfthe mathbfrisk mathbfof mathbfside mathbfeffects. This factor also precludes the use of the mathbfhighest mathbfavailable mathbfdose due to the elevated risk of muscle-related problems.


Q: Is Apo-Rosuvastatin prescribed to children?

Yes, the medication is mathbfindicated for specific uses in mathbfpediatric mathbfpatients, primarily those with mathbfFamilial mathbfHypercholesterolemia (an inherited form of high cholesterol). Official use begins at ages mathbf7 mathbfor mathbf8 mathbfyears mathbfand mathbfolder, depending on the specific condition.


Q: Are generic versions of rosuvastatin considered comparable to brand names?

Apo-Rosuvastatin is officially recognized as a mathbfgeneric mathbfequivalent to the innovator product. This means it contains the mathbfidentical mathbfactive mathbfcore mathbfsubstance (rosuvastatin) and is expected by regulatory bodies to provide the same therapeutic benefit.


Q: What kind of studies support the use of Apo-Rosuvastatin?

The official indications for this medication are supported by evidence from large-scale mathbfrandomized, mathbfplacebo-controlled mathbfclinical mathbftrials that examined its effects on blood fat levels and on reducing the rates of major cardiovascular events in various populations.


Q: Does taking Apo-Rosuvastatin help lower triglycerides as well as cholesterol?

Yes, official indications state the drug is used to reduce mathbfelevated mathbftriglycerides in the blood. It is also used to increase levels of mathbfHDL-C ('good' cholesterol), in addition to its primary action of lowering mathbfLDL-C ('bad' cholesterol).


Q: How do I know if Apo-Rosuvastatin is effective for me?

Official prescribing information indicates that mathbflipid mathbflevels should be mathbfchecked mathbfvia mathbfblood mathbftests within mathbf2 mathbfto mathbf4 mathbfweeks after starting the medication or adjusting the dose. This is the primary way healthcare professionals determine the therapeutic response.


Q: Can Apo-Rosuvastatin cause digestive upset?

Regulatory documents list several gastrointestinal reactions as mathbfCommon adverse events, meaning they occur in 1% to 10% of patients. These include mathbfnausea, mathbfconstipation, and mathbfabdominal mathbfpain, which are components of what is commonly called digestive upset.


Q: Is it necessary to avoid certain foods entirely while using Apo-Rosuvastatin?

Official administration guidelines state the medication can be taken mathbfwith mathbfor mathbfwithout mathbffood. While a cholesterol-lowering diet is an indicated adjunctive therapy, mathbfno mathbfspecific mathbffood mathbfitem is required to be mathbfentirely mathbfrestricted by the drug's regulatory documentation.

Advertisements

How should Apo-Rosuvastatin be stored and disposed of?

Official Storage and Disposal Requirements

Regulatory documents mandate strict storage conditions for Apo-Rosuvastatin tablets to maintain product stability. The medication must be kept in its original container with the cap tightly closed at controlled room temperature (typically 15 C to 30 C).

Protection from environmental factors is mandatory: the tablets must be stored away from excess moisture, excess heat, and direct light, and must not be frozen.

Child Safety and Waste Management

As a crucial safety measure, Apo-Rosuvastatin must always be stored in a secure location, out of the sight and reach of children and pets.

Disposal of unused or expired medication must follow official guidelines. The product must not be flushed down toilets or poured into drains. Instead, patients must consult a pharmacist or healthcare professional regarding approved drug take-back programs for proper disposal.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Apo-Rosuvastatin found in:

A-Z Index: